ClinicalTrials.gg
CompletedNCT05369403ADaptUpdated Feb 25, 2026Results posted

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

A Phase 3 interventional study of Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 37 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
21st of 24
86 · median 252
Started
2022
with 1 other
Phase 3
17 of 24
2 open now
Registered
12th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 21st largest by enrollment, is one of 2 that started in 2022, is one of 17 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must have prior treatment with dupilumab meeting one of the following conditions:

    • Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months.
    • Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment.
    • Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment.
  • Participants who have chronic AD that has been present for ≥1 year before screening.
  • Have EASI ≥16 at baseline
  • Have IGA score ≥3 (Scale of 0 to 4) at baseline
  • Have ≥10% body surface area (BSA) of AD involvement at baseline
  • Have a history of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.
  • Adolescents body weight must be ≥40 kg at baseline.

Exclusion criteria

Exclusion Criteria:

  • History of (HIV) infection or positive HIV serology at screening.
  • Have a current infection or chronic infection with virus (HBV) at screening (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA
  • Have a current infection with virus (HCV) at screening (that is, positive for HCV RNA
  • Have an uncontrolled chronic disease that might require multiple intermittent uses of oral at screening, as defined by the investigator.
  • Have uncontrolled asthma that

    • might require bursts of oral or systemic corticosteroids, or
    • required the following due to ≥1 exacerbations within 12 months before baseline

      • systemic (oral and/or parenteral) corticosteroid treatment, or
      • hospitalization for >24 hours.
  • Have known liver cirrhosis and/or chronic hepatitis of any etiology.
  • Had Dupilumab treatment within 4 weeks prior to baseline
  • Had prior treatment with tralokinumab.
  • Treatment with topical agents: corticosteroids, calcineurin inhibitors, Janus Kinase (JAK) inhibitors, or phosphodiesterase-4 inhibitors, such as crisaborole within 2 weeks prior to baseline
  • Treatment with any of the following agents within 4 weeks prior to the baseline

    • systemic or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, methotrexate, and other immunosuppressants)
    • small molecules (e.g. JAK inhibitors)
    • phototherapy and photochemotherapy for AD
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Lebrikizumab 250 mg Q2W

    Participants received a 500 milligram (mg) loading dose of Lebrikizumab subcutaneously (SC) once every 2 weeks (Q2W) at baseline and Week 2, followed by 250 mg SC once Q2W until Week 16.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W

    Participants who received Lebrikizumab 250 mg SC once Q2W until Week 16 and who did not achieve Investigator Global Assessment (IGA) 0 or 1 (clear or almost clear) or a 75% reduction in the Eczema Area and Severity Index (EASI) score from baseline (EASI-75) at Week 16 continued to receive 250 mg SC once Q2W until Week 24. Eligible participants entered the Continued Access Period, receiving the assigned same dose until the product was commercially available in the United States or discontinuation criteria were met.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W

    Participants who received Lebrikizumab 250 mg SC once Q2W until Week 16 and who achieved IGA 0 or 1 (clear or almost clear) or a 75% reduction in the EASI score from baseline (EASI-75) at Week 16 continued to receive 250 mg SC once Q2W until Week 24. Eligible participants entered the Continued Access Period, receiving the assigned same dose until the product was commercially available in the United States or discontinuation criteria were met.

    Drug: Lebrikizumab

Interventions

  • Administered SC

    Also known as: LY3650150, DRM06

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving EASI-75 at Week 24

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 24

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on the descriptors that best describe the overall appearance of the lesions at a given time point.

    Time frame: Baseline to Week 16

  3. Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 24

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on the descriptors that best describe the overall appearance of the lesions at a given time point.

    Time frame: Baseline to Week 24

  4. Percentage Change From Baseline in EASI Total Score From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

    Time frame: Baseline, Week 16

  5. Percentage Change From Baseline in EASI Score From Baseline to Week 24

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

    Time frame: Baseline, Week 24

  6. Change in EASI Score From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

    Time frame: Baseline, Week 16

  7. Change in EASI Score From Baseline to Week 24

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

    Time frame: Baseline, Week 24

  8. Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) at Week 16

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 responder is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: Week 16

  9. Percentage of Participants Achieving EASI-90 From Baseline to Week 24

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 responder is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: Baseline to Week 24

  10. Percentage of Participants With a Pruritus Numeric Rating Scale (NRS) of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 16

  11. Percentage of Participants With a Pruritus NRS of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 24

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 24

  12. Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 16

  13. Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 24

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 24

  14. Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 16

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Assessments were recorded daily by the participant using an electronic diary.

    Time frame: Baseline, Week 16

  15. Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 24

    Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Assessments were recorded daily by the participant using an electronic diary.

    Time frame: Baseline, Week 24

  16. Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 16

    Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

    Time frame: Baseline to Week 16

  17. Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 24

    Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

    Time frame: Baseline to Week 24

  18. Change From Baseline in Sleep-Loss Scale From Baseline to Week 16

    Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

    Time frame: Baseline, Week 16

  19. Change From Baseline in Sleep-Loss Scale From Baseline to Week 24

    Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

    Time frame: Baseline, Week 24

  20. Change From Baseline in Skin Pain NRS From Baseline to Week 16

    The Skin Pain NRS is an 11-point scale used by participants to rate their worst level of skin pain over the past 24 hours, with 0 indicating "no pain" and 10 indicating "worst pain imaginable."

    Time frame: Baseline, Week 16

  21. Change From Baseline in Skin Pain NRS From Baseline to Week 24

    The Skin Pain NRS is an 11-point scale used by participants to rate their worst level of skin pain over the past 24 hours, with 0 indicating "no pain" and 10 indicating "worst pain imaginable."

    Time frame: Baseline, Week 24

  22. Change From Baseline in Dermatology Life Quality Index (DLQI) From Baseline to Week 16

    The DLQI questionnaire designed for participants aged \>=16 years or more is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

    Time frame: Baseline, Week 16

  23. Change From Baseline in DLQI From Baseline to Week 24

    The DLQI questionnaire for participants aged 16 and above is a 10-item tool used to assess the impact of skin disease on quality of life. The 10 questions cover topics: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment over the previous week. Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively. Questions 3-10 have an additional response category of "not relevant," which is scored as "0." Questions are scored from 0 to 3. Total score ranges from 0 (no impact) to 30 (maximum impact), with higher scores indicating poorer quality of life.

    Time frame: Baseline, Week 24

  24. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) From Baseline to Week 16

    The CDLQI questionnaire designed for participants aged \<16 years and It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment).

    Time frame: Baseline, Week 16

  25. Change From Baseline in CDLQI From Baseline to Week 24

    The CDLQI questionnaire designed for participants aged \<16 years and It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment).

    Time frame: Baseline, Week 24

  26. Percentage Change From Baseline in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16

    SCORAD is validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on visual analog scale (VAS), where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease.

    Time frame: Baseline, Week 16

  27. Percentage Change From Baseline in SCORAD From Baseline to Week 24

    SCORAD is a validated tool for assessing the extent and intensity of AD. It consists of three components: A) the extent of AD as a percentage of each body area, with a maximum score of 100%; B) the severity of six specific symptoms (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) rated from 0 (none) to 3 (severe) for a maximum of 18 points; and C) the subjective assessment of itch and sleeplessness on a visual analog scale (VAS) from 0 (no itch/sleeplessness) to 10 (worst imaginable itch/sleeplessness) with a maximum score of 20. The total SCORAD score is calculated as A/5 + 7\*B/2 + C, ranging from 0 (no disease) to 103 (severe disease).

    Time frame: Baseline, Week 24

07

Results

Posted Mar 19, 2025

Participant flow

Treatment Period 1: Week 0 to Week 16
Participant flow — Treatment Period 1: Week 0 to Week 16
MilestoneLebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Started8600
Received at least one dose of drug8600
Intent-to-treat (itt) population8600
Completed5900
Not completed2700
Withdrew: Adverse event500
Withdrew: Protocol deviation100
Withdrew: Lack of efficacy100
Withdrew: Withdrawal by subject1200
Withdrew: Physician decision200
Withdrew: Lost to follow-up400
Withdrew: Enrolled but unable to comply with study procedures100
Withdrew: Enrolled but did not meet chronic disease duration requirement100
Treatment Period 2: Week 16 to Week 24
Participant flow — Treatment Period 2: Week 16 to Week 24
MilestoneLebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Started01841
Completed01537
Not completed034
Withdrew: Protocol deviation014
Withdrew: Withdrawal by subject010
Withdrew: Lost to follow-up010
Continued Access Period
Participant flow — Continued Access Period
MilestoneLebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Started0930
Completed0413
Not completed0517
Withdrew: Protocol deviation012
Withdrew: Withdrawal by subject006
Withdrew: Lost to follow-up004
Withdrew: Adverse event010
Withdrew: Non-compliance with study drug001
Withdrew: Physician decision001
Withdrew: Participant did not transition to commercially available lebrikizumab032
Withdrew: Discontinued in error-site failed to provide continued access protocol amendment with updated schema001

Outcome measures

PrimaryPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 1657.4 (46.9 to 67.3)
SecondaryPercentage of Participants Achieving EASI-75 at Week 24

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-75 responder is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI-75 at Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants Achieving EASI-75 at Week 2431.3 (16.1 to 51.8)71.8 (58.8 to 81.9)
SecondaryPercentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on the descriptors that best describe the overall appearance of the lesions at a given time point.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 1638.7 (29.2 to 49.2)
SecondaryPercentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 24

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on the descriptors that best describe the overall appearance of the lesions at a given time point.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2412.5 (4.2 to 31.6)48.7 (36.1 to 61.5)
SecondaryPercentage Change From Baseline in EASI Total Score From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage change
Percentage Change From Baseline in EASI Total Score From Baseline to Week 16
percentage changeLebrikizumab 250 mg Q2W
Percentage Change From Baseline in EASI Total Score From Baseline to Week 16-73.3 ± 23.06
SecondaryPercentage Change From Baseline in EASI Score From Baseline to Week 24

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage change
Percentage Change From Baseline in EASI Score From Baseline to Week 24
percentage changeLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage Change From Baseline in EASI Score From Baseline to Week 24-64.6 ± 23.26-82.4 ± 15.93
SecondaryChange in EASI Score From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change in EASI Score From Baseline to Week 16
score on a scaleLebrikizumab 250mg Q2W
Change in EASI Score From Baseline to Week 16-17.4 ± 9.34
SecondaryChange in EASI Score From Baseline to Week 24

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change in EASI Score From Baseline to Week 24
score on a scaleLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Change in EASI Score From Baseline to Week 24-17.4 ± 8.90-19.0 ± 8.29
SecondaryPercentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) at Week 16

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 responder is defined as a ≥ 90% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) at Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) at Week 1629.5 (20.9 to 39.8)
SecondaryPercentage of Participants Achieving EASI-90 From Baseline to Week 24

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 responder is defined as a ≥ 90% improvement from baseline in the EASI score.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI-90 From Baseline to Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants Achieving EASI-90 From Baseline to Week 2412.5 (4.2 to 31.6)35.9 (24.6 to 49.1)
SecondaryPercentage of Participants With a Pruritus Numeric Rating Scale (NRS) of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus Numeric Rating Scale (NRS) of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants With a Pruritus Numeric Rating Scale (NRS) of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 1653.2 (41.4 to 64.7)
SecondaryPercentage of Participants With a Pruritus NRS of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 24

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants With a Pruritus NRS of ≥4 Points at Baseline Who Achieve at Least 4-point Reduction From Baseline to Week 2453.8 (32.5 to 73.9)65.4 (49.3 to 78.6)
SecondaryPercentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 1672.9 (61.4 to 82.0)
SecondaryPercentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 24

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants With a Pruritus NRS of ≥3 Points at Baseline Who Achieve at Least 3-point Reduction From Baseline to Week 2476.9 (54.2 to 90.4)77.8 (62.4 to 88.0)
SecondaryPercentage Change From Baseline in Pruritus NRS Score From Baseline to Week 16

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Assessments were recorded daily by the participant using an electronic diary.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage change
Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 16
percentage changeLebrikizumab 250mg Q2W
Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 16-55.6 ± 41.78
SecondaryPercentage Change From Baseline in Pruritus NRS Score From Baseline to Week 24

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Assessments were recorded daily by the participant using an electronic diary.

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage change
Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 24
percentage changeLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage Change From Baseline in Pruritus NRS Score From Baseline to Week 24-30.0 ± 99.07-62.0 ± 35.74
SecondaryPercentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 16

Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 16
percentage of participantsLebrikizumab 250mg Q2W
Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 1641.7 (26.8 to 58.2)
SecondaryPercentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 24

Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 24
percentage of participantsLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage of Participants With a Sleep-Loss Scale of ≥2 Points at Baseline Who Achieve at Least 2-point Reduction From Baseline to Week 2440.0 (14.3 to 72.8)42.9 (24.1 to 64.0)
SecondaryChange From Baseline in Sleep-Loss Scale From Baseline to Week 16

Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Sleep-Loss Scale From Baseline to Week 16
score on a scaleLebrikizumab 250mg Q2W
Change From Baseline in Sleep-Loss Scale From Baseline to Week 16-1.0 ± 1.00
SecondaryChange From Baseline in Sleep-Loss Scale From Baseline to Week 24

Sleep loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all). Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Sleep-Loss Scale From Baseline to Week 24
score on a scaleLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Change From Baseline in Sleep-Loss Scale From Baseline to Week 24-0.7 ± 1.07-1.1 ± 0.91
SecondaryChange From Baseline in Skin Pain NRS From Baseline to Week 16

The Skin Pain NRS is an 11-point scale used by participants to rate their worst level of skin pain over the past 24 hours, with 0 indicating "no pain" and 10 indicating "worst pain imaginable."

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Skin Pain NRS From Baseline to Week 16
score on a scaleLebrikizumab 250mg Q2W
Change From Baseline in Skin Pain NRS From Baseline to Week 16-3.2 ± 2.96
SecondaryChange From Baseline in Skin Pain NRS From Baseline to Week 24

The Skin Pain NRS is an 11-point scale used by participants to rate their worst level of skin pain over the past 24 hours, with 0 indicating "no pain" and 10 indicating "worst pain imaginable."

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Skin Pain NRS From Baseline to Week 24
score on a scaleLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Change From Baseline in Skin Pain NRS From Baseline to Week 24-2.8 ± 3.51-3.3 ± 2.73
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) From Baseline to Week 16

The DLQI questionnaire designed for participants aged \>=16 years or more is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) From Baseline to Week 16
score on a scaleLebrikizumab 250mg Q2W
Change From Baseline in Dermatology Life Quality Index (DLQI) From Baseline to Week 16-8.7 ± 6.98
SecondaryChange From Baseline in DLQI From Baseline to Week 24

The DLQI questionnaire for participants aged 16 and above is a 10-item tool used to assess the impact of skin disease on quality of life. The 10 questions cover topics: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment over the previous week. Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively. Questions 3-10 have an additional response category of "not relevant," which is scored as "0." Questions are scored from 0 to 3. Total score ranges from 0 (no impact) to 30 (maximum impact), with higher scores indicating poorer quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in DLQI From Baseline to Week 24
score on a scaleLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Change From Baseline in DLQI From Baseline to Week 24-7.5 ± 7.13-9.5 ± 5.83
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) From Baseline to Week 16

The CDLQI questionnaire designed for participants aged \<16 years and It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment).

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) From Baseline to Week 16
score on a scaleLebrikizumab 250mg Q2W
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) From Baseline to Week 16-3.0 ± 7.96
SecondaryChange From Baseline in CDLQI From Baseline to Week 24

The CDLQI questionnaire designed for participants aged \<16 years and It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment).

Time frame:
Baseline, Week 24
Reported as:
Mean · score on a scale
Change From Baseline in CDLQI From Baseline to Week 24
score on a scaleLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Change From Baseline in CDLQI From Baseline to Week 24-1.0 ± NA-3.3 ± 9.45
SecondaryPercentage Change From Baseline in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16

SCORAD is validated tool for assessing the extent and intensity of AD, it consists of 3 components: A=extent of AD as a percentage of each defined body area and reported as sum of all areas, with maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0, mild=1, moderate=2, or severe=3 for maximum of 18 total points. C=subjective assessment of itch and sleeplessness recorded by participant on visual analog scale (VAS), where 0=no itch/no sleeplessness and 10=worst imaginable itch/sleeplessness with maximum score of 20. SCORAD total score is calculated: A/5+7\*B/2+ C to give total score range of 0 to 103, where 0=no disease to 103=severe disease.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage change
Percentage Change From Baseline in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16
percentage changeLebrikizumab 250mg Q2W
Percentage Change From Baseline in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16-55.7 ± 22.46
SecondaryPercentage Change From Baseline in SCORAD From Baseline to Week 24

SCORAD is a validated tool for assessing the extent and intensity of AD. It consists of three components: A) the extent of AD as a percentage of each body area, with a maximum score of 100%; B) the severity of six specific symptoms (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) rated from 0 (none) to 3 (severe) for a maximum of 18 points; and C) the subjective assessment of itch and sleeplessness on a visual analog scale (VAS) from 0 (no itch/sleeplessness) to 10 (worst imaginable itch/sleeplessness) with a maximum score of 20. The total SCORAD score is calculated as A/5 + 7\*B/2 + C, ranging from 0 (no disease) to 103 (severe disease).

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage change
Percentage Change From Baseline in SCORAD From Baseline to Week 24
percentage changeLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W
Percentage Change From Baseline in SCORAD From Baseline to Week 24-47.4 ± 27.07-60.1 ± 23.51

Adverse events

Collected over Baseline up to end of follow-up including continued access period (Up to 102 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lebrikizumab 250 mg Q2W0/86 (0%)1/86 (1.2%)38/86 (44.2%)
Lebrikizumab 250 mg Q2W to Q2W0/18 (0%)0/18 (0%)7/18 (38.9%)
Lebrikizumab 250 mg Q2W to Q4W0/41 (0%)1/41 (2.4%)14/41 (34.1%)
Most frequent serious events
Most frequent serious events
EventLebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Q2WLebrikizumab 250 mg Q2W to Q4W
Cerebral vascular occlusionNervous system disorders0/860/181/41
Rash morbilliformSkin and subcutaneous tissue disorders1/860/180/41
Most frequent other events
Showing 10 of 83
Most frequent other events
EventLebrikizumab 250 mg Q2WLebrikizumab 250 mg Q2W to Q2WLebrikizumab 250 mg Q2W to Q4W
Dermatitis atopicSkin and subcutaneous tissue disorders5/861/180/41
Tooth impactedGastrointestinal disorders0/861/180/41
ConjunctivitisInfections and infestations2/861/180/41
Covid-19Infections and infestations0/861/181/41
Otitis mediaInfections and infestations1/861/180/41
Viral upper respiratory tract infectionInfections and infestations1/861/182/41
ConcussionInjury, poisoning and procedural complications0/861/180/41
Hereditary non-polyposis colorectal cancer syndromeCongenital, familial and genetic disorders0/861/180/41
DiarrhoeaGastrointestinal disorders0/861/180/41
Otitis externaInfections and infestations0/861/180/41

Baseline characteristics

The intent-to-treat (ITT) population included all enrolled participants according to their planned intervention.

Age, Continuous
Age, Continuous(years)Lebrikizumab 250mg Q2W
Mean46.4 ± 20.00
Sex: Female, Male
Sex: Female, Male(Participants)Lebrikizumab 250mg Q2W
Female41
Male45
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lebrikizumab 250mg Q2W
Hispanic or Latino15
Not Hispanic or Latino69
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lebrikizumab 250mg Q2W
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American22
White57
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Lebrikizumab 250mg Q2W
United States86
08

Study locations

37 sites
  • River Region Dermatology and Laser
    Montgomery, Alabama 36117, United States
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Axon Clinical Research
    Inglewood, California 90301, United States
  • Avance Clinical Trials Inc
    Laguna Niguel, California 92677, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Wallace Medical Group, Inc.
    Los Angeles, California 90056, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Cura Clinical Research
    Sherman Oaks, California 91403, United States
  • UConn Health
    Farmington, Connecticut 06030-2840, United States
  • Encore Medical Research of Boynton Beach
    Boynton Beach, Florida 33436, United States
  • Total Vein and Skin LLC
    Boynton Beach, Florida 33437, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Hollywood Dermatology
    Hollywood, Florida 33021, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • Ziaderm Research, LLC.
    North Miami Beach, Florida 33162, United States
  • Olympian Clinical Research
    Tampa, Florida 33615, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Dermatology and Advanced Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Dermatology and Skin Cancer Specialists, LLC
    Rockville, Maryland 20850, United States
  • Allcutis Research, Inc.
    Beverly, Massachusetts 01915, United States
  • Oakland Hills Dermatology
    Auburn Hills, Michigan 48326, United States
  • The Derm Institute of West Michigan
    Caledonia, Michigan 49316, United States
  • Revival Research Institute - Troy
    Troy, Michigan 48084, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Allcutis Research, Inc
    Portsmouth, New Hampshire 03801, United States
  • Windsor Dermatology, P.C.
    East Windsor, New Jersey 08520, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • OptiSkin Medical
    New York, New York 10128, United States
  • Dermatologists of Greater Columbus
    Bexley, Ohio 43209, United States
  • Dermatology and Skin Surgery Center, PC
    Exton, Pennsylvania 19341, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Complete Dermatology
    Sugar Land, Texas 77479, United States
  • Spokane Dermatology Clinic
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Silverberg JI, Ackerman L, Bagel J, Stein Gold L, Blauvelt A, Rosmarin D, Chovatiya R, Zirwas M, Yosipovitch G, Waibel J, Murase JE, Lockshin B, Weisman J, Atwater AR, Proper J, Silk M, Pierce E, Piruzeli MLB, Montmayeur S, Schuster C, Zhong J, Rueda MJ, Pillai S, Simpson E. Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study. Dermatol Ther (Heidelb). 2026 Feb;16(2):1309-1330. doi: 10.1007/s13555-025-01644-3. Epub 2026 Jan 19. PubMed 41553700 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jan 2024, 12 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 11, 2022
StartActual
Dec 19, 2022
Primary completionActual
Jan 11, 2024
CompletionActual
Feb 5, 2025
Results first posted
Mar 19, 2025
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05369403
Responsible party
Sponsor
First posted
May 11, 2022
Start date
Dec 19, 2022
Primary completion
Jan 11, 2024
Completion
Feb 5, 2025
Results posted
Mar 19, 2025
Last update
Feb 25, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion